Table 1.
Baseline characteristics and subject disposition across the SUSTAIN 1 to 5 trials
| SUSTAIN 1: Semaglutide vs. placebo | SUSTAIN 2: Semaglutide vs. sitagliptin 100 mg | SUSTAIN 3: Semaglutide vs. exenatide ER 2.0 mg | SUSTAIN 4: Semaglutide vs. IGlar | SUSTAIN 5: Semaglutide add‐on to insulin vs. placebo | |
|---|---|---|---|---|---|
| 30 wk | 56 wk | 56 wk | 30 wk | 30 wk | |
| Baseline characteristics, mean (SD) a | |||||
| Age (years) | 53.7 (11.3) | 55.1 (10.0) | 56.6 (10.7) | 56.5 (10.4) | 58.8 (10.1) |
| Men (%) | 54.3 | 50.6 | 55.3 | 53.0 | 56.1 |
| Diabetes duration (y) | 4.2 (5.5) | 6.6 (5.1) | 9.2 (6.3) | 8.6 (6.3) | 13.3 (7.8) |
| Body weight (kg) | 91.9 (23.8) | 89.5 (20.3) | 95.8 (21.5) | 93.5 (21.8) | 91.7 (21.0) |
| HbA1c (%) | 8.1 (0.9) | 8.1 (0.9) | 8.3 (1.0) | 8.2 (0.9) | 8.4 (0.8) |
| HbA1c (mmol/mol) | 64.5 (9.3) | 64.8 (10.1) | 67.7 (10.4) | 65.8 (9.7) | 67.9 (9.2) |
| FPG (mg/dL) | 175.7 (48.2) | 169.4 (40.7) | 189.0 (48.7) | 175.3 (51.2) | 155.9 (53.7) |
| BMI (kg/m 2 ) | 32.9 (7.7) | 32.5 (6.2) | 33.8 (6.7) | 33.0 (6.5) | 32.2 (6.2) |
| Subject disposition, N (%) | |||||
| Randomized | 388 | 1231 | 813 | 1089 | 397 |
| Exposed | 387 (99.7) | 1225 (99.5) | 809 (99.5) | 1082 (99.4) | 396 (99.7) |
| Trial completers | 359 (92.5) | 1163 (94.5) | 743 (91.4) | 1020 (93.7) | 380 (95.7) |
| Premature treatment discontinuation | 47 (12.1) | 146 (11.9) | 167 (20.6) | 130 (12.0) | 43 (10.9) |
| Semaglutide 0.5 mg | 17 (13.3) | 53 (13.0) | N/A | 49 (13.5) | 14 (10.6) |
| Semaglutide 1.0 mg | 16 (12.3) | 61 (14.9) | 82 (20.3) | 55 (15.3) | 16 (12.2) |
| Comparator | 14 (10.9) | 32 (7.9) | 85 (21.0) | 26 (7.2) | 13 (9.8) |
| Subjects with imputed value for end‐of‐treatment body weight | 93 (24.0) | 271 (22.1) | 238 (29.4) | 177 (16.4) | 82 (20.7) |
Abbreviations: BMI, body mass index; exenatide ER, exenatide extended release; FPG, fasting plasma glucose; IGlar, insulin glargine; N, number of subjects; SD, standard deviation.
a
Values are mean (SD) unless otherwise indicated.